Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with gram-positive infections

Revista Espanola de Quimioterapia

Volumn 23, Issue 1, 2010, Pages 27-35

  Sirvent, Josep Maria ^a   Piñeiro, Laura ^a   De La Torre, Mari ^a   Motjé, Montse ^a   De Batlle, Jordi ^a   Bonet, Alfons ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Critically ill patients; Gram positive infections; Linezolid; Microbiologic eradication; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CATHETER INFECTION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENTEROCOCCUS; ERADICATION THERAPY; FEMALE; GRAM POSITIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SURGICAL INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VOMITING;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 77956540326     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1977-1999. Clin Infect Dis 2001; 32, (Suppl2):S114-32.
2. Cuevas O, Cercenado E, Goyanes MJ, Vindel A, Trincado P, Boquete T, et al. Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986-2006). Enferm Infecc Microbiol Clin 2008; 26:269-277
3. Mensa J, Barberán J, Llinares P, Picazo J, Bouza E, Alvarez-Lerma F, et al. Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter 2008; 21:234-258
4. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilatorassociated pneumonia: retrospective analysis of two doubleblind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394
5. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188:760-766
6. Weigelt J, Itani KM, Stevens D, Lau W, Dryden M, Knirsch C, and the Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-2266
7. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
8. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538-1548
9. Hosmer DV, Lemeshow S. Confidence interval estimates of an index of quality performance based on logistic regression models. Stat Med 1995; 14:2161-2172
10. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597-607.
11. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM et al. Infections Study Group. Randomized comparison of linezolid (PNU100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-3413
12. Muñoz P, Rodriguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E, GAME Study Group. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007; 13:211-215
13. Barcenilla Gaite F, Jover Saenz A, Vallverdú Vidal M, Castellana Perello D. New therapeutic options for the treatment of multiresistant bacteria in the ICU. Rev Esp Quimioter 2008; 21:9-13.
14. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicenter study. J Antimicrob Chemother 2004; 53:345-355
15. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60:1361-1369
16. Grau S, Rubio-Terrés C. Pharmacoeconomics of linezolid. Expert Opin Pharmacother 2008; 9:987-1000.
17. Gavaldà L, Masuet M, Beltran J, Garcia M, Garcia D, Sirvent JM, et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006; 27:1264-1267
18. Wenisch C, Laferl H, Szell M, Smolle KH, Grisold A, Bertha G, et al. A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia. Infection 2006; 34:148-154
19. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:53-66.
20. Olaechea Astigarraga PM, Garnacho Montero J, Grau Cerrato S, Rodriguez Colomo O, Palomar Martínez M, Zaragoza Crespo R, et al. GEIPC-SEIMC; GTEI-SEMICYUC recommendations for antibiotic treatment of gram positive cocci infections in the critical patient. Med Intensiva 2007; 31:294-317. (Pubitemid 47219637)